Post-merg­er, In­da­lo rais­es $9M; Spark rais­ing $331M; No word on Shkre­li’s fate

→ A St. Louis-based biotech named In­da­lo Ther­a­peu­tics — for­mer­ly An­te­grin — has picked up the first $9 mil­lion of a planned $26 mil­lion in­vest­ment, ac­cord­ing to a Form D filed with the SEC. The fil­ing in­cludes a va­ri­ety of high-pro­file VCs, in­clud­ing Ben Aus­pitz at F-Prime and Pe­ter Bar­rett at At­las. The com­pa­ny was cre­at­ed last fall through a merg­er of An­te­grin Ther­a­peu­tics and Cas­ca­dia Ther­a­peu­tics. It’s fo­cused on fi­bro­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.